Mental Health Blogs

After the first day of a trial against GlaxoSmithKline for allegedly hiding birth defects data from users of its anti-depressant Paxil, Bloomberg reports:

“An executive of GlaxoSmithKline Plc, the world’s second-biggest drugmaker, talked about burying negative studies linking its antidepressant drug Paxil to birth defects, according to a company memo introduced in trial.

“‘If neg, results can bury,’ Glaxo executive Bonnie Rossello wrote in a 1997 memo on what the company would do if forced to conduct animal studies on the drug. The memo was read during opening statements in the trial of a lawsuit brought by the family of an injured child.”

There will apparently be many more documents–ones unseen by the FDA and Congress–introduced at this trial, so stay tuned.

After several years of revelations around Paxil and GSK, I simply don’t know what to say anymore.

Go to Source

Related posts:

1. Glaxo Must Pay $2.5 Million In Paxil Birth Defects Case
2. Glaxo Had Ghostwriting Program To Promote Paxil
3. Paxil Birth Defects Testimony Now Online
4. Glaxo Negligent, Not Outrageous
5. Court Rules Glaxo Must Reveal Paxil Birth Defects Emails